German drugmaker BioNTech on Monday lowered its guidance for full-year revenue, citing COVID-19 uptake and price levels, ...

Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.53, ...

Fintel reports that on November 8, 2024, Goldman Sachs upgraded their outlook for BioNTech SE - Depositary Receipt () ...

Driven by the early approval of its updated COVID-19 vaccine, BioNTech far exceeded analysts’ expectations in the third ...

In a report released yesterday, Chris Shibutani from Goldman Sachs upgraded BioNTech SE (BNTX – Research Report) to a Buy, with a price ...

Ugur Sahin; Chief Executive Officer, Member of the Management Board; Biontech SE Oezlem Tuereci; Chief Medical Office, Member of the Management Board; Biontech SE Welcome to BioNTech's third ...

Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on BioNTech SE (BNTX – Research Report). The associated price ...

BioNTech SE reported a surprise profit in the third quarter, helped by solid sales of its variant-adapted Covid-19 vaccines. Mainz, Germany-based BioNTech posted earnings of €0.81 ($0.88 ...

Ugur Sahin; Chief Executive Officer, Member of the Management Board; Biontech SE Oezlem Tuereci; Chief Medical Office, Member of the Management Board; Biontech SE Welcome to BioNTech's third quarter ...

MAINZ, Germany, November 4, 2024 (GLOBE NEWSWIRE)-- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today reported financial results for the three and nine months ended September 30, 2024 and ...